SCHEMBL1354331

SCHEMBL1354331

OCCC(c1ccccc1)c1cc(Br)ccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
HPGD P15428 5/20 0.56
LMNA P02545 3/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
KMT2A Q03164 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
TP53 P04637 2/20 0.49
MEN1 O00255 2/20 0.49
CHRM2 P08172 2/20 0.46
CHRM5 P08912 2/20 0.46
CHRM1 P11229 2/20 0.46
CHRM3 P20309 2/20 0.46
HRH1 P35367 2/20 0.46
HTR2A P28223 2/20 0.46
ESR1 P03372 1/20 0.46
CHRM4 P08173 1/20 0.46
KCNE1 P15382 1/20 0.46
PTGS1 P23219 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12134294 0.86 LMNA (0.62) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL4060523 0.81 MAPT (0.68) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL12200293 0.81 CHRM2 (0.46) L3MBTL1HPGDLMNAMAPTKMT2A
SCHEMBL820438 0.80 CHRM3 (0.74) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL4663933 0.80 CHRM3 (0.74) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL29462882 0.79 HPGD (0.69) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL4662337 0.79 HPGD (0.54) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL815785 0.79 CHRM3 (0.72) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL10808262 0.78 HPGD (0.60) L3MBTL1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL11890506 0.78 CHRM2 (0.46) L3MBTL1HPGDLMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011141932-A2 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS INTAS PHARMACEUTICALS LIMITED (IN) 2011-11-17 WO disclosed
US-20110282094-A1 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS INTAS PHARMACEUTICALS LIMITED (IN) 2011-11-17 US disclosed
WO-2011141932-A2 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS INTAS PHARMACEUTICALS LIMITED (IN) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282094-A1 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS HPD, COMT, PNMT L3MBTL1 1111/4885HPGD 359/4885LMNA 2384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.